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Abstract
Pulmonary complications, in the form of hepatopulmonary syndrome (HPS), portopul-
monary hypertension (PPH), and hepatic hydrothorax (HH), are rare occurrences in 
patients with portal hypertension and liver cirrhosis. These complications are associated 
with high morbidity and mortality. The only effective therapy is liver transplantation in 
patients who are suitable. In this chapter, each condition will be outlined in detail from 
clinical presentations to diagnosis and treatment as well as the challenges that clinicians 
may have encountered in managing patients with these complications.
Keywords: hepatopulmonary syndrome, portopulmonary hypertension, hepatic 
hydrothorax, liver transplantation
1. Introduction
Pulmonary complications in patients with chronic liver disease and portal hypertension 
include hepatopulmonary syndrome (HPS), portopulmonary complications (PPH), and hepatic 
hydrothorax (HH) (Figure 1). They are associated with increased morbidity and mortality and 
therefore, high suspicion of index is required to make earlier diagnosis and subsequently, to 
early treatment. The only effective treatment is liver transplantation (LT). All patients suitable 
for liver transplantation should be screened for potential pulmonary complications because 
earlier diagnosis gives better survival post liver transplantation. HPS is more common than 
PPH and HH, and the best chance of survival in these patients is LT. Among all the three condi-
tions, HH carries the best prognosis.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Hepatopulmonary syndrome
2.1. Background
Hepatopulmonary syndrome (HPS) is first described in 1977 by Kennedy and Knudson [1] 
and defined as a defect in arterial oxygenation caused by the presence of intrapulmonary 
vascular dilatation (IVPD) in the context of portal hypertension [2] (Figure 2). The estimated 
prevalence of HPS in liver cirrhosis is 4–32% [3]. In patients who were accessed for LT, the 
prevalence of HPS is approximately 10–30% [4]. HPS is usually diagnosed during the sixth 
decade of life and there is no specific association with gender or underlying cause of liver 
disease or model of end stage liver disease (MELD) [4, 5]. The established 5-year survival rate 
was 20% for HPS patients versus 32–63% for patients without HPS [5, 6].
Pulmonary complicaons
Hepato-pulmonary 
syndrome
Porto-pulmonary 
hypertension
Hepac hydrothorax
Pathogenesis
1) Impaired oxygenaon
2) Intra-pulmonary 
vasodilataon
3) background of portal 
hypertension
Invesgaons
Pulse oximetry
Arterial blood gas
CXR
Contrast ECHO
Macroaggreated perfusion 
scan
Pathogenesis
1) elevated mean arterial 
pressure
2) increased pulmonary 
vascular resistance
3) background of portal 
hypertension
Invesgaons
Pulse oximetry
Arterial blood gas
CXR
Transthoracic echocardiogram 
Right heart catheterisaon
Treatment 
Oxygen
Liver transplantaon in 
case of suitable paents
Treatment 
Oxygen
Oral agents: Prostacyclin 
analogues 
(prostanoids)/Phosphodiester
ase 5 inhibitors and endothelin 
receptor antagonists
Liver transplantaon in case of 
suitable paents
Pathogenesis
1) renin-angiotensin 
acvaon causing sodium 
and water retenon
2) fluid translocaon through 
small defect in diaphragma
Invesgaons
Pulse oximetry
Arterial blood gas
CXR
Transthoracic 
echocardiogram 
Treatment 
Medical: dietary educaon, 
diurecs, pleural aspiraon, 
thoracocentesis, 
paracentesis
Non-surgical procedures: 
TIPSS, Pleux drain
Surgical: pleurodesis, shunt 
surgery and repair of 
diaphragmac defect and 
finally liver transplantaon 
when all others are not 
effecve. 
Figure 1. A step-wise approach to pulmonary complications of liver cirrhosis.
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2.2. Clinical features
Most patients with HPS present with dyspnea, orthopnea, platypnea, cyanosis, spider naevi, 
and finger clubbing [3, 7]. Platypnoea or orthodeoxia is defined as the presence of shortness 
of breath (dyspnoea) that worsens while sitting or standing and relieved by lying down. It 
is a common feature described in patients with HPS [7]. When patients with liver cirrhosis 
present with shortness of breath, the investigations should be done as early as feasible to 
avoid the delay in the diagnosis. Early diagnosis leads to reduction in patient’s morbidity and 
mortality. The severity of HPS can be distinguished based on the level of hypoxemia as per 
the European Respiratory Task Force (Table 1) [8].
2.3. Pathogenesis
The pathogenesis of HPS is still unclear but the hallmark is thought to be due to intrapul-
monary vasodilatation (IVPD), especially at the level of pre-capillary and capillary vaso-
dilation [7]. IVPD is mediated by a number of endogenous vasoactive molecules, mainly 
endothelin-1 (ET-1) and nitric oxide (NO) [3, 9]. Portal hypertension increased the production 
 
 
Portal hypertension 
Intrapulmonary vascular vasodilatation 
Impaired oxygenation 
Hepato-pulmonary syndrome 
Figure 2. The sequence in development of HPS in liver cirrhosis.
Degree of severity Level of hypoxaemia (PaO
2
)
Mild ≥80 mmHg
Moderate ≥60–<80 mmHg
Severe ≥50–<60 mmHg
Very severe <50 mmHg
Table 1. The severity of HPS as per level of hypoxaemia.
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of  vasoconstrictor ET-1, which stimulates the production of the ETB receptor at the level of 
the pulmonary microcirculation, with subsequent increase in eNOS activity causing vaso-
dilatation [7, 9]. As a result of IVPD, nearly 20% or more of the cardiac output bypasses the 
functioning alveoli [2]. IVPD then causes arterial deoxygenation by three mechanisms: venti-
lation/perfusion mismatch, intrapulmonary shunting, and limitation of oxygen diffusion [7].
Angiogenesis is also considered to be an important phenomenon in the development of HPS 
[10] through upregulation of the vascular endothelial growth factor. Other mechanism sug-
gested from experimental studies was vasodilation via increased carbon monoxide produc-
tion through haem oxygenase [7]. The proposed pathogenesis of HPS was shown in Figure 3.
2.4. Investigations
In most centers, patients will usually undergo routine cardiopulmonary investigations during 
LT assessment. Bedside pulse oximetry is the first line screening investigation and oxygen satu-
ration of less than 96%, has a sensitivity of 100% and specificity of 88% to detect PaO
2
 < 70 mmHg 
[7, 11]. Arterial blood gas (ABG) sampling is required for the diagnosis of HPS to calculate the 
Alveolar-arterial (A-a) gradient [7]. PA-aO
2
 gradient is the most important marker in diagnosing 
early stage of HPS [7] and the European Respiratory Society Task Force recommends a PA-aO
2
 ≥ 
15 mmHg for the diagnosis of HPS and the level of PaO
2
 will determine the severity of the HPS 
[10] (Table 1). In suspected patients with HPS, ABG was performed on room air with patient 
sitting down first and the procedure is repeated 15 to 20 minutes in the standing up position. 
Orthodeoxia, which manifests as a decrease in PaO
2
 of ≥4 mmHg or ≥5% from the supine to 
the upright position [12], and the increase in PaO
2
 while breathing 100% oxygen, which should 
reach above 300 mmHg [7]. Orthodeoxia is a consequence of the increased V/Q mismatch and 
decreased cardiac output following the change from the supine to the upright position [7].
Figure 3. The pathogenesis of hepatopulmonary syndrome.
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Chest radiography shows prominent pulmonary vascular markings in bilateral lower lobes, 
but finding is not specific for HPS [2]. Pulmonary function test should be performed to rule 
out other associated intrinsic pulmonary disorders. Contrast-enhanced echocardiography is 
the most sensitive test to demonstrate intrapulmonary shunting disease [2]. It is done using 
intravenous injections of agitated saline or indocyanine green to produce bubbles of at least 
15 microns in diameter [2]. Normally, these microbubbles are trapped in the pulmonary 
vasculature and absorbed, but in intracardiac right to left shunts, these microbubbles are 
seen in the left heart within the first three cardiac cycles [7]. In HPS, the bubbles are seen in 
the left heart after the third heartbeat, usually between the third and sixth heartbeat due to 
intra-pulmonary shunting [2]. Studies have shown that transesophageal echocardiography 
is more sensitive than transthoracic echocardiography in demonstrating intrapulmonary 
shunting [7].
99 m Technetium-macroaggregated albumin (Tc-99 m MAA) lung perfusion scan is used 
widely in the diagnosis of HPS (Figure 4). Albumin macroaggregates with more than 20 μm 
in diameter are normally entrapped in the pulmonary vasculature [2]. In patients with intra-
pulmonary shunts, these albumin macroaggregates escape from the pulmonary vasculature 
and are taken up by other organs [2]. Normally, less than 5% of isotope reaches brain circula-
tion compared to the lung, but in HPS patients, the fraction is more than 6% [7]. The major 
disadvantage of Tc-99 m MAA scan is its inability to differentiate intra-cardiac from intrapul-
monary shunting. Pulmonary angiography is invasive, and hence, it is only reserved for those 
who did not have response to 100% oxygen therapy [7]. The baseline investigations and the 
findings found in HPS are illustrated in Table 2.
Figure 4. Whole body (Tc-99 m MAA) scan showed an increased uptake in within the lungs and thyroid with well 
visualization in the brain, kidneys, and liver.
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2.5. Treatment
2.5.1. Medical treatment
Patients who experience severe dyspnea at rest and evidence of hypoxemia clinically should 
receive oxygen therapy [10]. Many studies have looked into treatment of HPS with nitric oxide 
inhalation, low consumption of L-arginine using methylene blue, aspirin, antibiotic usage to 
reduce intestine’s bacterial translocation, somatostatin, indomethacin, garlic, and transjugu-
lar intrahepatic portosystemic shunt (TIPS), but none of them have not shown any particular 
benefit as long-term treatment of HPS [7].
Recent pilot randomized controlled study with norfloxacin did not show any improvement 
in gas exchange of HPS patient [13]. Initial studies suggested that garlic may have a role in 
the treatment of HPS by altering nitric oxide production [7]. A recent randomized controlled 
trial showed garlic supplementation, which was associated with a 24.66% increase in baseline 
arterial oxygen levels and 28.35% decrease in alveolar-arterial oxygen gradient [14]. It also 
shown that garlic supplementation may be beneficial in patients with HPS for the reversal of 
intrapulmonary shunts as well as for reducing hypoxemia and mortality, although study with 
higher number of patients are required to show clinical effectiveness [14].
One of the factors involved in the pathogenesis of HPS was tumor necrosis factor-alpha (TNF-a) 
and overproduction of TNF-a cause vasodilatation [4]. Hence, treatment with pentoxifylline (an 
inhibitor of TNF-a) although in recent pilot study [15] showed that pentoxifylline did not improve 
arterial oxygenation in advanced HPS, and tolerance was limited by gastrointestinal toxicity.
Enhanced pulmonary production of nitric oxide (NO) has been implicated in the patho-
genesis of HPS, and NO inhibition with N(G)-nitro-L-arginine methyl ester (L-NAME) 
in both animals and humans with HPS has improved arterial hypoxemia [16]. A study 
[16] investigating the effect of nebulized L-NAME in patients with HPS showed that 
Screening methods Findings
Pulse oximetry Oxygen saturation <96%
Chest radiograph Increased vascular markings
Lung function tests Normal or reduction FVC or FEV1
Reduction in diffusing capacity of the lungs for carbon 
monoxide (DLCO-co)
Diagnostic tests Findings
Arterial blood gas analysis AaO
2
 ≥ 15 mmHg or
AaO
2
 ≥ 20 mmHg (in patients above 64 years of age)
Contrast echocardiography Bubbles in the left cavities between the fourth and sixth 
beat
99 m Tc-MAA Cerebral uptake ≥6%
Table 2. Screening and investigative methods used in HPS.
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the treatment decreased exhaled NO, mixed venous nitrite/nitrate, and cardiac output 
although systematic and pulmonary vascular resistance were increased. In contrast, ven-
tilation-perfusion mismatching, intrapulmonary shunt, and, in turn, arterial deoxygen-
ation remained unchanged [16].
2.5.2. Transjugular intrahepatic portosystemic shunt (TIPSS)
Recent systematic reviews of 10 studies with 12 patients showed that TIPSS is technically 
feasible to perform in patients with HPS, but overall benefit is unclear [17]. The current man-
agement did not advise TIPSS in patients with HPS.
2.5.3. Liver transplantation (LT)
The only effective treatment available for HPS is liver transplantation (LT), although LT 
is invasive and carries a high risk. Hence, patients should be accessed thoroughly prior to 
consideration of LT. After LT, 85% patients had significant improvement in gas exchange, 
although it can take up to 1 year for the abnormalities to normalize [2]. The mortality is higher 
for patient with HPS who underwent LT than those without HPS and the mortality is higher 
for those with marked hypoxemia (PaO
2
 < 50 mmHg) and intrapulmonary shunting (shunt 
fraction > 20%) [2]. The established 5-year survival rate was 23% for HPS patients and 67% for 
patients without HPS [18]. For patients with HPS who are on LT waiting list should be moni-
tored closely to prevent worsening of the conditions. The most challenging post LT is severe 
hypoxemia post-operative period with prolonged respiratory weaning that often resulted in 
death. Ten-year survival after LT in HPS patients stands at 64% [10] and post LT mortality 
rates obtained in these studies range between 7.7 and 33% [10].
Recent study showed that patients with HPS presented higher cardiac output, lower systemic 
vascular resistance, and higher progesterone and estradiol levels than patients without HPS 
[19]. The study showed that LT produced normalization of intrapulmonary vasodilatation in 
all patients as well as hyperdynamic circulation and hence, is a useful therapeutic option in 
patients with HPS [19]. Normalization of sex hormone levels after LT suggests that they could 
play a pathogenic role in the development of HPS [19].
2.5.4. Other treatment options
One of the recent management options for life-threatening hypoxemia in HPS patients is 
extracorporeal membrane oxygenation (ECMO) [20]. Monsel et al. reported the use of ECMO 
in preparation of LT in patients with refractory hypoxemia caused by a combination of acute 
respiratory distress syndrome (ARDS) and HPS [21]. The preliminary data showed that 
ECMO allowed the performance of successful LT by controlling gas exchange [3]. Auzinger et 
al. also reported the successful case of using ECMO for severe refractory hypoxemia after LT 
in HPS patients [20]. It could facilitate early ventilator weaning, thus prevented the need for 
the prolonged use of sedation and reduced complication associated with interventions [20]. 
However, the effectiveness of ECMO still has to be proven by future randomized trials.
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3. Portopulmonary hypertension
3.1. Background
Portopulmonary syndrome (PPH) was first described in 1951 by Mantz and Craige [22]. PPH 
is characterized by the presence of elevated mean pulmonary hypertension in patients with 
portal hypertension due to increased pulmonary vascular resistance [4]. It is found in 2–10% 
of patients with cirrhosis [2] and reported among 5–8% of the patients with CLD who have 
undergone liver transplantation [23].
A recent retrospective review conducted in treatment-naïve patients with PPH within the 
United Kingdom national registry showed that patients with PPH had survival rates of 85, 60, 
and 35% at 1, 3, and 5 years [24]. The study mentioned that the prevalence of PPH was found 
to be 0.85 cases per 1 million and the mean age of diagnosis was 53 years [24]. Alcohol and 
hepatitis C were found to be the most common causes of PPH [24].
PPH results from arterial vasoconstriction linked to remodeling of the vasculature of the lung 
caused by prolonged portal hypertension and subsequently lead to pulmonary arterial hyper-
tension (PAH) [9]. The condition is more common in females and in patients with autoim-
mune hepatitis [7, 25]. PPH can occur at any age but more common in fourth or fifth decade 
of life [4]. PPH occurs 4–7 years after patients are diagnosed with portal hypertension [26]. 
The severity of liver disease does not correlate with the severity of PPH. Without treatment, 
estimated 1-year survival in PPH is around 60% [23, 27].
3.2. Clinical features
Most patients are asymptomatic but clinical features of liver disease will be apparent. Patients 
usually present with features of right-sided heart failure such as dyspnea, orthopnea, chest pain, 
fatigue, and syncope [9]. On clinical examination, patient may present with tricuspid regurgita-
tion murmur, loud pulmonary (P2) sound, diastolic murmur of pulmonary regurgitation, and 
features of right-sided heart failure evident by the presence of elevated jugular venous pres-
sure, pulsatile liver, peripheral edema, and ascites [9]. The severity of PPH is classified based on 
degree of MPAP values: mild (25–35 mmHg), moderate (35–50 mmHg), and severe (>50 mmHg) 
[9].
The European Cardiologic Society and the European Respiratory Society Task Force have 
defined the diagnostic criteria for PPH as follow in Table 3 [28]. According to the World 
Health Organization classification, PPH is located within PAH group 1 [29].
Diagnostic criteria for PPH
Mean pulmonary arterial pressure (mPAP) >25 mmHg
Pulmonary vascular resistance (PVR) >240 dyn s cm−5
Pulmonary capillary wedge pressure <15 mmHg
Table 3. Diagnostic criteria for portopulmonary hypertension (PPH).
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3.3. Pathogenesis
The exact pathophysiology behind PPH is poorly understood but histologically, it is thought 
to be similar to the pathogenesis of idiopathic pulmonary arterial hypertension (PAH) [29]. 
Hyperdynamic circulatory state and high cardiac output are the hallmarks in most of the 
patients with PPH leading to increased shear stress on the pulmonary circulation [29]. Due 
to vascular shear stress, vasoactive, proliferative, and angiogenic mediators (including endo-
thelin 1 (ET-1), vasoactive intestinal peptide, serotonin, thromboxane A2, interleukin 1, gluca-
gon, and secretin) were released which lead to arterial changes seen in PPH [2, 4, 23, 27]. The 
main pathological abnormalities include proliferate arteriopathy, obliteration of the vascular 
lumen by endothelial and smooth muscle cells, formation of plexiform lesions, necrotizing 
arteritis, fibrinoid necrosis, and in-situ thrombi [23, 27]. Due to portosystemic shunts, bacterial 
endotoxins were found in pulmonary circulation from gastrointestinal tract and the recruit-
ment of interstitial macrophages to clear those endotoxins also contribute to the development 
of PPH [30].
Genetic polymorphisms may play a role in the development of PPH. Finally, vasodilating 
mediators, such as nitric oxide (NO) and prostaglandin I
2
 (prostacyclin), may be decreased in 
PPH [29]. Prostacyclin synthase, the enzyme responsible for prostacyclin synthesis, has been 
demonstrated to be deficient in the pulmonary endothelium of patients with PPH [4]. The 
illustration pathogenesis of PPH is shown in Figure 5.
3.4. Investigations
Since patient can be asymptomatic, high suspicion is required to diagnose this condition ear-
lier, which can lead to earlier treatment and better prognosis. All baseline investigations such 
as ECG, CXR, blood gas analysis, and lung function tests have poor prognostic yield and 
did not reflect severity of PPH. In patient with PPH, CXR might show a prominent main 
pulmonary artery, cardiomegaly due to enlarged right cardiac chambers, and increased vas-
cularity in the upper lobes [2, 4, 9]. Pulmonary function tests in patients with PPH would 
show decreased lung diffusion capacity and reduced lung volume [2, 4]. In arterial blood gas 
analyses, hypoxemia and hypocapnia associated with an elevated alveolar-arterial oxygen 
gradient would be seen [2].
Transthoracic echocardiogram showed right ventricular hypertrophy and right atrium dil-
atation, which is not usually specific to PPH [23, 27]. Transthoracic echocardiogram (TTE) 
is the screening tool used initially and it can identify patients with elevated pulmonary 
arterial systolic pressure (PASP). In those patients with elevated PASP, the next investigation 
is right heart catheter which can confirm the diagnosis of PPH. Usually, RV systolic pressure 
<30 mmHg was used to exclude PPH and if it is >50, patient is highly likely to have PPH [23]. 
Cardiac output (CO), mean pulmonary arterial pressure (mPAP), mean pulmonary arterial 
occlusion pressure (mPAOP), and pulmonary vascular resistance (PVR) can help to determine 
the nature and severity of the PPH [2, 27]. There are three main causes of elevated mPAP in 
liver disease patients and those are cirrhotic cardiomyopathy due to left ventricular dysfunc-
tion, the typical high-output state of cirrhosis, and PPH [27]. Table 4 illustrates the difference 
findings noted in each condition.
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The severity of PPH and the progression of disease during the course of disease in patients 
with portal hypertension can only be investigated through invasive right heart catheterization. 
Hence, it will be useful to develop a sensitive biomarker which can detect disease presence, 
predict the severity, and treatment response. A recent prospective multicentre case-control 
study which studied the plasma level of macrophage migration inhibitory factor (MIF) in 
PPH patients seemed to show promising results [31]. It showed that MIF was higher in both 
the systemic and pulmonary circulations of patients with PPH compared with controls and 
correlated with hemodynamic indices of disease severity [31]. High levels of MIF were associ-
ated with an increased risk of death and MIF production may play a role in disease patho-
genesis of PPH [31]. MIF can be an ideal novel biomarker in detecting disease presence and 
severity [31].
3.5. Treatment
Treatment strategies for PPH are derived from studies of idiopathic PAH and the aim of ther-
apy is to provide symptomatic relief, to improve the quality of life and exercise capacity, and to 
facilitate liver transplant [23]. The only effective treatment in patients with PPH is liver trans-
plantation in patients who are suitable after careful assessment. Medical therapies that have 
Figure 5. The pathogenesis of portopulmonary hypertension.
Cardiac output mPAP mPAPOP PVR
Hyperdynamic state Elevated Elevated Normal Decreased
LV dysfunction Low Elevated Elevated Elevated
PPH Low Elevated Low Elevated
Table 4. The difference findings for each conditions.
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been tried for PPH include endothelin receptor antagonists, phosphodiesterase 5 inhibitors, 
and prostacyclin analogs [2, 23, 27]. There are limited data evaluating the long-term survival of 
patients with PPH managed with medical therapy alone. Recent study from UK showed that 
phosphodiesterase 5 inhibitors were the most frequently used targeted therapy (63%) followed 
by prostacyclin analogs (12.7%), and endothelin receptor antagonists (10%) [32].
3.5.1. General medical treatment
In patient with significant hypoxemia, oxygen therapy is needed for improvement of symp-
toms. For those with significant edema and ascites, diuretics should be initiated. In patients 
with PPH, they are at risk of thrombosis and hence anticoagulation is recommended. 
However, in patients with liver cirrhosis had increased risk of variceal bleeding due to under-
lying portal hypertension and clinical judgment is required prior to starting anticoagulation 
in these group of patients.
Calcium channel blockers can be used due to their acute vasoreactive properties in PAH but 
can be dangerous in patients with PPH since it can result in worsening of portal hypertension 
because of their mesenteric dilatation properties [2, 23, 27]. TIPSS are not recommended in 
PPH since it can deteriorate PPH because of acute increase in preload causing increased cardiac 
output and mPAP, and then leads to worsening right ventricular strain and dysfunction [29].
3.5.2. Specific therapies for PPH
The therapies specific for PPH targeted to improve pulmonary vasoconstriction and vascular 
remodeling by altering three pathways: Prostacyclin analogs (prostanoids), phosphodiester-
ase 5 inhibitors, and endothelin receptor antagonists [2, 9, 27, 33]. Pulmonary vasodilators 
treatment should be employed with the aim of lowering mPAP < 35 mmHg, to minimize the 
risk of graft failure and to improve the overall outcome [42].
3.5.3. Prostacyclin derivatives
They are potent pulmonary as well as systemic vasodilators, and have antiplatelet aggregat-
ing and antiproliferative effects [27]. The most commonly used prostacyclin is epoprostenol 
and it is the only treatment that has been shown to improve survival in idiopathic PAH [27].
3.5.4. Endothelin receptor antagonists
Bosentan is an oral dual effective, nonselective receptor antagonist that blocks both endothe-
lin A and B receptors [27], and it has been shown to be effective in the treatment of PPH show-
ing clinical, functional, and hemodynamic benefits without significant hepatotoxicity in some 
small retrospective case series [29]. Bosentan is probably the therapy of choice for patients 
with PPH as it potentially improves pulmonary as well as portal hypertension [29]. It is poten-
tially hepatotoxic and may cause deterioration in liver enzymes in about 10% of patients, and 
hence, close monitoring is needed [29]. A recent study showed that Child-Pugh B cirrhosis 
with PPH had significantly larger hemodynamic improvement with bosentan treatment [34]. 
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It was also found that plasma concentrations of bosentan were higher in patients with child B 
cirrhosis than those observed in idiopathic PAH [34].
3.5.5. Phosphodiesterase 5 inhibitors
Phosphodiesterase-5 inhibitor therapy is efficacious in other causes of WHO group I pulmonary 
arterial hypertension [32]. They inhibit the growth of pulmonary vascular smooth muscle cells 
and lower mean pulmonary artery pressure and pulmonary vascular resistance by mediating 
vasodilation through guanosine monophosphate [2, 27]. Sildenafil is commonly used in PPH 
and reported to be effective in reducing mPAP and PVR [29]. Sildenafil is approved in a dose 
of 20 mg three times a day for treatment of PPH [35], and it should be considered as a bridging 
therapy before liver transplant for patients with PPH to delay the progression of the disease.
A recent single center retrospective study showed that sildenafil therapy resulted in improve-
ment of WHO functional class with significant decrease in PVR, mPAP, and increase in cardiac 
output but no change in 6-min walk test over the period of 6 months treatment [32]. A recent 
retrospective study of all patients with PPH treated by oral pulmonary vasoactive drugs (PVD) 
(bosentan, ambrisentan, sildenafil, tadalafil) showed that oral PVD improved MPAP, PVR, and 
6-min walk distance [36]. The study showed that oral PVD are safe, better tolerated in patients 
with cirrhosis, and did not showed any worsening of cirrhosis and these treatments improved 
hemodynamic conditions allowing patients access to liver transplantation eligibility [36].
3.5.6. Liver transplantation
LT is the definitive therapy for patient with PPH when medical therapy fails. LT should be 
considered in patients with mean pulmonary artery pressure (MPAP) <35 mmHg or MPAP 
between 35 and 50 mmHg with pulmonary vascular resistance (PVR) <250 dyn s cm−5 [23, 37]. 
PPH is diagnosed in 2–6% of liver transplantation (LT) candidates [38]. Without LT, the sur-
vival rate for patients with PPH was found to be 38% at 3 years and 28% at 5 years [37]. Due 
to the severity of the condition and high mortality associated with it, patient with PPH should 
be assessed careful before considering LT. Perioperative mortality in patients with mean PAP 
>35 mmHg is significantly higher compared to those with mPAP < 35 mmHg [4, 23]. The 
outcome is worse in patients with moderate to severe PPH [mean pulmonary artery pressure 
(MPAP) ≥ 35 mm Hg] and associated with a perioperative mortality rate of 50% [37, 38].
Therefore, patient should be treated with medical therapy while awaiting LT to delay the 
progression of disease as well as to improve perioperative risk. The goal of therapy in patients 
with PPH, who are candidates for liver transplants, is to reduce mPAP <35 mmHg and the 
PVR < 400 dyn s cm−5 before proceeding to liver transplant [29].
Patients on liver transplant waiting list are prioritized based on the model of end-stage liver 
disease (MELD) score but in patients with PPH, potentially important factors such as severity 
of PPH is not included which may affect survival. Recent retrospective cohort study of patients 
in the Organ Procurement Transplantation Network (OPTN) database with hemodynamics 
consistent with PPH [defined as mean pulmonary arterial pressure (mPAP) >25 mmHg and 
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pulmonary vascular resistance (PVR) ≥ 240 dynes.sec.cm-5 who were approved for a PPH-
MELD exception between 2006 and 2014 showed that initial native MELD score and initial 
PVR were the only significant univariate predictors of waitlist mortality and remained signifi-
cant predictors in a multivariate model [39]. The study showed that PVR and mPAP were not 
significant predictors of post-transplant mortality [39].
According to the European Respiratory Society Task Force, patients with mean pulmonary artery 
pressure < 35 mmHg can undergo a liver transplant, patients with mean pulmonary artery pres-
sure of 35–45 mmHg should receive vasodilator therapy before transplant, and patients with 
mean pulmonary artery pressure > 45 mmHg should receive vasodilator therapy only [4, 7].
4. Hepatic hydrothorax
4.1. Background
Hepatic hydrothorax (HH) is a more common clinical entity compared to HPS and PPH and 
carries the best prognosis [9]. HH accounts for 2–3% of total pleural effusions [40]. However, 
in patients with portal hypertension, HH occurred in 5–10% of cases [41].
HH is caused by the accumulation of transudative effusion in patients who did not have 
underlying cardiopulmonary disease [42]. Majority of HH was noted on right side in 79.5% of 
cases followed by left sided and bilateral in 17.5 and 3%, respectively [40].
Since the pleural space is relatively small compared to the abdominal cavity with low compli-
ance of the thoracic cavity, patients can become symptomatic with as little as 500 ml accumula-
tion of fluid [42]. Like ascites, HH can become spontaneously infected, a condition known as 
spontaneous bacterial empyema (SBEM), which carries a mortality of up to 20% [42]. The inci-
dence of SBEM was noted to be 13% in a prospective study [43] and interestingly, up to 40% of 
SBEM patients are not associated with incidence of spontaneous bacterial peritonitis (SBP) [43].
4.2. Clinical features
The clinical presentation is usually found in patients with cirrhosis and portal hypertension, 
i.e., ascites, spider naevi, asterixis, hepatosplenomegaly, and caput medusa. Patients with HH 
can present with pulmonary symptoms as in shortness of breath, cough, hypoxemia, or respi-
ratory failure associated with large pleural effusions [40]. SBEM should always be suspected 
when patients develop fever, pleuritic chest pain, or features of liver decompensation.
4.3. Pathogenesis
The pathogenesis of HH is similar to those leading to ascites in portal hypertension [40, 41]. 
Portal hypertension and splanchnic vasodilatation are the main pathways leading to fluid accu-
mulation as a result of decrease in effective blood volume which then activate renin-angioten-
sin system leading to sodium and water retention [9]. Particularly in HH, it is thought to be a 
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consequence of ascitic fluid translocation through congenital diaphragmatic defects into the 
pleural cavity [42]. These defects, normally covered with pleuroperitoneum, were most fre-
quently seen in the right hemi-diaphragm and usually smaller than 1 cm in size [42]. Ascites 
accumulation increases the intraperitoneal pressure which causes rupture of the pleuroperito-
neal membrane and as a result, ascitic fluid can move into the low pressure pleural space [42]. 
This explanation for the appearance of hepatic hydrothorax is supported by studies showing 
intraperitoneal-injected radiotracer activity in the pleural fluid of such patients [44]. HH can 
happen due to hypoalbuminemia resulting in decreased colloid osmotic pressure [45] and lym-
phatic leakage from the thoracic duct [46].
4.4. Investigations
Patients with portal hypertension with pulmonary clinical features should be investigated 
thoroughly to rule out other causes of pulmonary and cardiac disorders. HPS and PPH should 
be investigated as part of differential diagnosis. The presence of pleural effusions is usually 
detected by thorough respiratory examination with findings of dullness to percussion, medi-
astinal shift, diminished or inaudible breath sounds, and pleural friction rub. In clinically sus-
pected patients, pleural effusions can be confirmed with one of the imaging modalities such 
as chest X-ray (Figure 6), ultrasound scan, or CT chest. Echocardiogram should be performed 
to rule out underlying cardiac causes of effusions.
Figure 6. Chest X-ray showed the presence of right-sided pleural effusion.
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Pleural fluid should be examined to rule out other causes leading to pleural fluid such as infec-
tion, inflammation, and malignancy. Pleural fluid should be aspirated using ultrasound and 
the sample should be sent for cell count, gram stain, culture, cytology, pH, total protein, albu-
min, lactate dehydrogenase (LDH), and amylase. Diagnosis of transudate is based on Light’s 
criteria, which is shown in Table 5 [47], since HH is transudate in nature.
In patients with SBEM, pleural fluid has high Polymorphonuclear cell counts >250 cells/mm3 
with positive culture or >500 cells/mm3 in patients with negative culture without any evidence 
of underlying chest infection/pneumonia or exudative features of infection [40].
4.5. Treatment
4.5.1. Medical therapy
The role of medical therapies is to relieve symptoms and prevent the complications of HH in 
patients awaiting liver transplantation or to palliate symptoms in those who are not trans-
plant candidate [42]. Treatment is similar to the treatment of ascites which include dietary 
salt restriction, diuretic therapy, and drainage of fluid either from abdomen or pleural space.
The management of dietary sodium is important to prevent re-accumulation of fluids and 
dietary education should be given to patients. Diuretic therapies with furosemide 40–80 mg 
once daily with or without addition of spironolactone 50–400 mg OD are used in patients 
who are tolerant of diuretic therapy. Urinary sodium should be checked before and during 
therapy to adjust diuretic dosage as per clinical response. In patients with refractory ascites, 
the other treatment modalities can be used. These include paracentesis, thoracentesis, inser-
tion of chest drain tube, indwelling tunneled pleural catheter (PleurX) insertion, insertion of 
transjugular intrahepatic portosystemic shunt (TIPSS), pleurodesis, shunt surgery, and repair 
Light's criteria
Pleural fluid total protein/serum total protein ratio <0.5
Pleural fluid LDH/serum LDH <0.6
Pleural fluid LDH < two thirds of the upper limit of normal serum LDH
Other investigative parameters
Total protein <2.5 g/dl
Pleural fluid lactic dehydrogenase (LDH) <200 IU
Serum pleural to fluid albumin gradient >1.1 g/dl
Glucose level similar to that of serum
pH 7.4–7.55
Polymorphonuclear count <250 cells/mm3
Table 5. Characteristics of pleural fluid in HH.
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of diaphragmatic defect [40, 41, 48–51]. Each treatment has its own advantages and disadvan-
tages and should be selected as per patient’s clinical condition.
In patients with HH and large volume ascites, ascites should be drained before draining pleural 
fluid to prevent the rapid accumulation of fluid in the pleural space after thoracentesis due to 
decreased intrathoracic pressure [40]. Thoracentesis is used for large pleural effusion in patient 
with significant dyspnea. Pleural fluid should be drained not more than 2 L of fluid at any time 
point to prevent expansion pulmonary edema. If patients required regular thoracentesis, they 
should be considered for therapies that provide long term symptom relief. Indwelling tun-
neled pleural catheter (PleurX) insertion is usually considered for patients in palliative setting.
TIPSS is effective in controlling ascites and hepatic hydrothorax, although the procedure did 
not improve the prognosis of patients with end-stage liver cirrhosis [40, 51]. TIPSS should 
be considered in patients with compensated liver cirrhosis and the factors associated with 
increased mortality in patients who had TIPSS are age >60 years, Child Pugh class C, pres-
ence of pre-TIPSS high model for end-stage liver disease (MELD) score >15 and high pre-TIPS 
creatinine levels >2 mg/dl [51]. Patients whose had high risk features described above should 
be considered for LT.
In patients with SBEM, the management is to treat underlying infection with broad spectrum 
antibiotics with or without inserting large bore chest drain tube.
4.5.2. Liver transplantation
In patients with refractory ascites who are Child Pugh C cirrhosis, LT should be considered 
first prior to other therapies. The presence of HH does not lead to more post-operative compli-
cations, and long-term survival is similar to other indications of liver transplantation [40, 41]. 
Patient should be managed conservatively with medical therapy while awaiting LT.
5. Conclusion
Pulmonary complications (HPS, PPH, and HH) are rare occurrence in patients with liver cirrhosis 
and portal hypertension. In patients with these conditions carry a significant morbidity and mor-
tality and therefore, strong clinical suspicion is required to make earlier diagnosis. There are mul-
tiple medical therapies available for each condition in literature but most of the treatments are not 
effective. The only effective treatment that alters the clinical prognosis is liver transplantation and 
hence, patients with these conditions should be screened and assessed for the suitability of LT.
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